PhD, Molecular Biology (Minor in Genetics), Iowa State University, 2006
MS, Statistics, Iowa State University, 2006
Research Interests
Dr. Zhang leverages her expertise in Biostatistics, Bioinformatics, and Molecular Biology to advance interdisciplinary biomedical research. Her research centers on applied biostatistics, bioinformatics, and machine learning for studying disease molecular mechanisms, identifying biomarkers for disease prognosis and treatment, conducting health outcomes research, and addressing health disparities across various fields, including cancer, infectious diseases, Alzheimer's disease, and more. Her expertise encompasses experimental and clinical trial design, power analysis, survival analysis, logistic regression, linear mixed-effects models, longitudinal data analysis, multiple comparisons, correlative studies, omics data analysis, signaling pathway analysis, and machine learning algorithms. Throughout her career, Dr. Zhang has collaborated extensively with biomedical investigators, serving as both principal investigator and co-investigator on numerous federal grants and producing impactful findings. Her research has consistently been supported by prestigious federal funding, including P01s, SPOREs, R01s, U01s, and DOD grants. Currently, she serves as the Director and PI of the Biostatistics and Bioinformatics Core for a newly funded P01 (PI: Dr. Amer, OSU) dedicated to studying long COVID.
Prior to joining USF, Dr. Zhang was an Associate Professor in the Department of Biomedical Informatics at The Ohio State University. She also held roles as a senior member of the Biostatistics and Bioinformatics Shared Resource at the Comprehensive Cancer Center and as the lead faculty biostatistician for the Leukemia, Lymphoma, and Myeloma group at OSU.
Awards/Honors
Inaugural Award for Excellence in Collaborative Research, Department of Biomedical Informatics (The Ohio State University - 2020)
Recent Publications
Zhang, X., Huang, Y., Yang, Y., Wang, Q. E., & Li, L Advancements in prospective single-cell lineage barcoding and their applications in researchGenome Res. , 2024.
Kuang, Z., Miao, J., & Zhang, X Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancerFront Immunol. 15(1327449) , 2024.
Prasad, C. B., Oo, A., Liu, Y., Qiu, Z., Zhong, Y., Li, N., Singh, D., Xin, X., Cho, Y. J., Li, Z., Zhang, X., Yan, C., Zheng, Q., Wang, Q. E., Guo, D., Kim, B., & Zhang, J. The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity.Nat Commun. 15(1) : 4667, 2024.
Prislusky, M. I., Lam, J. G. T., Contreras, V. R., Ng, M., Chamberlain, M., Pathak-Sharma, S., Fields, M., Zhang, X., Amer, A. O., & Seveau, S. The septin cytoskeleton is required for plasma membrane repairEMBO Rep. 25(9) : 3870-3895, 2024.
Denlinger, N., Song, N. J., Zhang, X., Jeon, H., Peterson, C., Wang, Y., Reynolds, K., Bolz, R. M., Miao, J., Song, C., Wu, D., Chan, W. K., Bezerra, E., Epperla, N., Voorhees, T. J., Brammer, J., Kittai, A. S., Bond, D. A., Sawalha, Y.,…Yang, Y. Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphomaBlood Adv. 8(12) : 3140-3153, 2024.
